Moleculin Biotech CS (MBRX)

$0.61 +0.00 (0.51%)
Market Cap 4.31M
Revenue (ttm) 0.00
Net Income (ttm) -33.56M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 656,800
Avg Vol 1,419,472
Day's Range N/A - N/A
Shares Out 7.10M
Stochastic %K 83%
Beta 1.84
Analysts Strong Sell
Price Target $21.00

Company Profile

Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases. The company is also developing WP1066 portfolio, including WP1066, WP1193, and WP1220, which are immune/transcription modulators designed to...

Industry: Biotechnology
Sector: Healthcare
Phone: 713 300 5160
Address:
5300 Memorial Drive, Suite 950, Houston, United States
Traveladvisor
Traveladvisor Aug. 19 at 3:33 PM
$MBRX
0 · Reply
Traveladvisor
Traveladvisor Aug. 19 at 3:32 PM
$MBRX A big catalyst is coming, partnership? The short squeeze is ready, get in while you can.
0 · Reply
Traveladvisor
Traveladvisor Aug. 18 at 1:38 PM
$MBRX
1 · Reply
ShangVXO
ShangVXO Aug. 18 at 12:07 PM
Been tapped into @_ProfessorGamma for a minute now. The way they spot some of these plays before they run is nuts! Wise to be paying attention to this account, give him a proper follow 👍 $MBRX and $NIVF on my radar
2 · Reply
Big_Zack22
Big_Zack22 Aug. 17 at 8:01 PM
$MBRX Hold on a good consolidation. Next hope 0.85 then we fly
0 · Reply
Stormra
Stormra Aug. 17 at 7:53 PM
$MBRX Not one post all day accept mine.????
0 · Reply
Stormra
Stormra Aug. 17 at 2:27 PM
$MBRX Hello.... Lets go!!!
0 · Reply
Big_Zack22
Big_Zack22 Aug. 17 at 1:19 AM
$MBRX The recent sell-off created an asymmetrical upside setup. MBRX has a funded cash runway into Q1 2027 following its $9.3M offering, removing immediate dilution risk. Unblinded interim data for its Phase 2/3 MIRACLE trial showed 50-57% complete remission rates (vs 29% control) with zero cardiotoxicity, solving anthracycline heart-damage risks. Part A enrollment finishes by Sept 2026, with major unblinded results due Dec-Feb. At current oversold levels, clinical catalysts can easily trigger a powerful rally.
0 · Reply
Big_Zack22
Big_Zack22 Aug. 17 at 12:17 AM
$MBRX will aggressively recover, all points to an upward.
0 · Reply
Komba123
Komba123 Aug. 16 at 8:55 PM
$FAMI $MBRX $SPY im Bullish but it’s not 50% short float, it’s about 7%
0 · Reply
Latest News on MBRX
Moleculin Biotech Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of Pivotal MIRACLE Trial

Aug 14, 2026, 8:30 AM EDT - 5 days ago

Moleculin Biotech Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of Pivotal MIRACLE Trial

MBRX

Moleculin Biotech Proxy statement: Proxy filing

Aug 14, 2026, 8:00 AM EDT - 5 days ago

Moleculin Biotech Proxy statement: Proxy filing

Moleculin Biotech Quarterly report: Q2 2026

Aug 13, 2026, 7:00 AM EDT - 6 days ago

Moleculin Biotech Quarterly report: Q2 2026

Moleculin Biotech Earnings release: Q2 2026

Aug 13, 2026, 7:00 AM EDT - 6 days ago

Moleculin Biotech Earnings release: Q2 2026

Moleculin Announces Pricing of $9.3 Million Public Offering

Jul 31, 2026, 10:12 AM EDT - 19 days ago

Moleculin Announces Pricing of $9.3 Million Public Offering

MBRX

Moleculin Biotech updates preliminary blinded results from MIRACLE trial Part A

2026-07-31T12:36:19.000Z - 19 days ago

Moleculin Biotech updates preliminary blinded results from MIRACLE trial Part A

MBRX

Moleculin's MIRACLE R/R AML Trial Reports Positive Interim Data with 37% Blinded CRc in Venetoclax-Failed Patients

Jul 31, 2026, 8:10 AM EDT - 19 days ago

Moleculin's MIRACLE R/R AML Trial Reports Positive Interim Data with 37% Blinded CRc in Venetoclax-Failed Patients

MBRX

Moleculin Biotech Registration statement: Registration filing

Jul 31, 2026, 8:00 AM EDT - 19 days ago

Moleculin Biotech Registration statement: Registration filing

Moleculin Biotech Registration statement: Registration filing

Jul 30, 2026, 8:00 AM EDT - 20 days ago

Moleculin Biotech Registration statement: Registration filing

Moleculin Biotech files to sell 4.57M shares of common stock, warrants

2026-07-29T13:45:59.000Z - 21 days ago

Moleculin Biotech files to sell 4.57M shares of common stock, warrants

MBRX

Moleculin Biotech Registration statement: Registration filing

Jul 29, 2026, 8:00 AM EDT - 21 days ago

Moleculin Biotech Registration statement: Registration filing

Moleculin CEO, Walter Klemp, Highlights Positive Preliminary MIRACLE Trial Results in Virtual Investor "What This Means" Segment

Jul 6, 2026, 8:33 AM EDT - 6 weeks ago

Moleculin CEO, Walter Klemp, Highlights Positive Preliminary MIRACLE Trial Results in Virtual Investor "What This Means" Segment

MBRX

Moleculin Biotech Slides: Corporate presentation

Jul 1, 2026, 8:00 AM EDT - 7 weeks ago

Moleculin Biotech Slides: Corporate presentation

Moleculin Biotech announces unblinded efficacy results from MIRACLE trial Part A

2026-06-30T13:05:26.000Z - 7 weeks ago

Moleculin Biotech announces unblinded efficacy results from MIRACLE trial Part A

MBRX

Moleculin Reports Positive Phase 2/3 MIRACLE Interim Results, With Annamycin Complete Remission Rates 3-fold Greater than Control

Jun 30, 2026, 8:30 AM EDT - 7 weeks ago

Moleculin Reports Positive Phase 2/3 MIRACLE Interim Results, With Annamycin Complete Remission Rates 3-fold Greater than Control

MBRX

Independent Market Research Finds Strong Physician Intent to Prescribe Moleculin's Annamycin in Relapsed/Refractory AML

Jun 5, 2026, 8:29 AM EDT - 2 months ago

Independent Market Research Finds Strong Physician Intent to Prescribe Moleculin's Annamycin in Relapsed/Refractory AML

MBRX

Moleculin CEO, Walter Klemp, Highlights 45 Subject Enrollment Milestone in Recent Virtual Investor “What This Means” Segment

Jun 4, 2026, 8:31 AM EDT - 2 months ago

Moleculin CEO, Walter Klemp, Highlights 45 Subject Enrollment Milestone in Recent Virtual Investor “What This Means” Segment

MBRX

Moleculin Presents ASCO 2026 Data Demonstrating No Detectable Cardiotoxicity with Annamycin Despite Exposure Levels Far Exceeding Conventional Anthracycline Limits

May 29, 2026, 8:21 AM EDT - 2 months ago

Moleculin Presents ASCO 2026 Data Demonstrating No Detectable Cardiotoxicity with Annamycin Despite Exposure Levels Far Exceeding Conventional Anthracycline Limits

MBRX

Moleculin Highlights Abstract Accepted for Poster Presentation at the 2026 ASCO Annual Meeting Highlighting Cardiac Safety Data for Annamycin

May 21, 2026, 5:02 PM EDT - 3 months ago

Moleculin Highlights Abstract Accepted for Poster Presentation at the 2026 ASCO Annual Meeting Highlighting Cardiac Safety Data for Annamycin

MBRX

Moleculin Reports First Quarter 2026 Financial Results and Provides Clinical Update on Pivotal MIRACLE Trial

May 15, 2026, 8:30 AM EDT - 3 months ago

Moleculin Reports First Quarter 2026 Financial Results and Provides Clinical Update on Pivotal MIRACLE Trial

MBRX

Moleculin Biotech Quarterly report: Q1 2026

May 14, 2026, 4:00 PM EDT - 3 months ago

Moleculin Biotech Quarterly report: Q1 2026

Moleculin Biotech Earnings release: Q1 2026

May 14, 2026, 4:00 PM EDT - 3 months ago

Moleculin Biotech Earnings release: Q1 2026

Moleculin Biotech expects first unblinding of MIRACLE trial data by June 30

2026-05-13T14:09:53.000Z - 3 months ago

Moleculin Biotech expects first unblinding of MIRACLE trial data by June 30

MBRX

Moleculin Announces Imminent MIRACLE Trial Unblinding as Blinded Data Continue to Significantly Outperform Historical Benchmarks

May 13, 2026, 8:00 AM EDT - 3 months ago

Moleculin Announces Imminent MIRACLE Trial Unblinding as Blinded Data Continue to Significantly Outperform Historical Benchmarks

MBRX

Independent Cleveland Clinic Review Finds No Clinically Significant Cardiotoxicity with Moleculin's Annamycin in R/R AML Patients Dosed Beyond Conventional Anthracycline Limits

May 12, 2026, 9:30 AM EDT - 3 months ago

Independent Cleveland Clinic Review Finds No Clinically Significant Cardiotoxicity with Moleculin's Annamycin in R/R AML Patients Dosed Beyond Conventional Anthracycline Limits

MBRX

Moleculin Biotech issued liposomal Annamycin patent in Hong Kong

2026-05-08T15:28:54.000Z - 3 months ago

Moleculin Biotech issued liposomal Annamycin patent in Hong Kong

MBRX

Moleculin Biotech Secures Strategic Additional Patent, Strengthening Global Positioning of Annamycin

May 8, 2026, 8:45 AM EDT - 3 months ago

Moleculin Biotech Secures Strategic Additional Patent, Strengthening Global Positioning of Annamycin

MBRX

Moleculin's Annamycin Extends Survival by More Than 60% in Metastatic Pancreatic Cancer Preclinical Models - Data Presented at AACR 2026

Apr 23, 2026, 8:25 AM EDT - 4 months ago

Moleculin's Annamycin Extends Survival by More Than 60% in Metastatic Pancreatic Cancer Preclinical Models - Data Presented at AACR 2026

MBRX

Moleculin Announces Abstract Accepted for Poster Presentation at the 2026 ASCO Annual Meeting

Apr 21, 2026, 8:36 AM EDT - 4 months ago

Moleculin Announces Abstract Accepted for Poster Presentation at the 2026 ASCO Annual Meeting

MBRX

Moleculin Releases Next CEO Corner Segment Highlighting Annamycin's Non-Cardiotoxic Profile

Apr 7, 2026, 8:36 AM EDT - 4 months ago

Moleculin Releases Next CEO Corner Segment Highlighting Annamycin's Non-Cardiotoxic Profile

MBRX

Moleculin Biotech management to meet with Maxim

2026-04-02T15:10:34.000Z - 4 months ago

Moleculin Biotech management to meet with Maxim

MBRX

Moleculin Biotech files to sell 6.37M shares of common stock for holders

2026-03-27T20:07:31.000Z - 5 months ago

Moleculin Biotech files to sell 6.37M shares of common stock for holders

MBRX

Moleculin Biotech Registration statement: Registration filing

Mar 27, 2026, 8:00 AM EDT - 5 months ago

Moleculin Biotech Registration statement: Registration filing

Moleculin Biotech Transcript: The 38th Annual Roth Conference

Mar 24, 2026, 3:00 PM EDT - 5 months ago

Moleculin Biotech Transcript: The 38th Annual Roth Conference

Moleculin Biotech announces enrollment milestone in MIRACLE trial

2026-03-23T13:23:25.000Z - 5 months ago

Moleculin Biotech announces enrollment milestone in MIRACLE trial

MBRX

Moleculin Hits 45 Subject Enrollment Milestone, Triggering Final Countdown to Mid-2026 MIRACLE Trial Data Readout

Mar 23, 2026, 8:31 AM EDT - 5 months ago

Moleculin Hits 45 Subject Enrollment Milestone, Triggering Final Countdown to Mid-2026 MIRACLE Trial Data Readout

MBRX

Moleculin Biotech reports FY25 EPS ($28.42) vs. ($189.14) last year

2026-03-19T12:41:28.000Z - 5 months ago

Moleculin Biotech reports FY25 EPS ($28.42) vs. ($189.14) last year

MBRX

Moleculin Biotech sees cash runway into 3Q26

2026-03-19T12:41:00.000Z - 5 months ago

Moleculin Biotech sees cash runway into 3Q26

MBRX

Moleculin Reports Full Year 2025 Financial Results and Confirms Highly Anticipated 45-Patient Interim Data Unblinding in Pivotal MIRACLE Trial On Track for Mid-2026

Mar 19, 2026, 8:36 AM EDT - 5 months ago

Moleculin Reports Full Year 2025 Financial Results and Confirms Highly Anticipated 45-Patient Interim Data Unblinding in Pivotal MIRACLE Trial On Track for Mid-2026

MBRX

Moleculin Biotech Earnings release: Q4 2025

Mar 18, 2026, 7:00 AM EDT - 5 months ago

Moleculin Biotech Earnings release: Q4 2025

Moleculin Biotech Annual report: Q4 2025

Mar 18, 2026, 7:00 AM EDT - 5 months ago

Moleculin Biotech Annual report: Q4 2025

Moleculin Biotech Slides: Corporate presentation

Mar 18, 2026, 7:00 AM EDT - 5 months ago

Moleculin Biotech Slides: Corporate presentation

Moleculin to Present at 38th Annual ROTH Conference

Mar 17, 2026, 9:05 AM EDT - 5 months ago

Moleculin to Present at 38th Annual ROTH Conference

MBRX

Moleculin Releases Next CEO Corner Segment Highlighting MIRACLE Study

Mar 11, 2026, 9:00 AM EDT - 5 months ago

Moleculin Releases Next CEO Corner Segment Highlighting MIRACLE Study

MBRX

Moleculin Biotech Proxy statement: Proxy Filing

Mar 9, 2026, 8:00 AM EDT - 5 months ago

Moleculin Biotech Proxy statement: Proxy Filing

Moleculin Biotech Proxy statement: Proxy Filing

Feb 26, 2026, 7:00 AM EST - 6 months ago

Moleculin Biotech Proxy statement: Proxy Filing

Moleculin Biotech announces exercise of warrants for $8.3M gross proceeds

2026-02-19T13:44:53.000Z - 6 months ago

Moleculin Biotech announces exercise of warrants for $8.3M gross proceeds

MBRX

Moleculin Announces Exercise of Warrants for $8.3 Million Gross Proceeds

Feb 19, 2026, 8:39 AM EST - 6 months ago

Moleculin Announces Exercise of Warrants for $8.3 Million Gross Proceeds

MBRX

Moleculin MIRACLE Trial Delivers 40% Preliminary Blinded CRc Rate (n=30)

Feb 18, 2026, 8:20 AM EST - 6 months ago

Moleculin MIRACLE Trial Delivers 40% Preliminary Blinded CRc Rate (n=30)

MBRX

Moleculin Biotech Slides: Corporate presentation

Feb 18, 2026, 6:00 AM EST - 6 months ago

Moleculin Biotech Slides: Corporate presentation

Moleculin Biotech announces notice of allowance for JPO covering Annamycin

2026-02-17T14:00:40.000Z - 6 months ago

Moleculin Biotech announces notice of allowance for JPO covering Annamycin

MBRX

Moleculin Announces Notice of Allowance for Japanese Patent Covering Annamycin

Feb 17, 2026, 8:35 AM EST - 6 months ago

Moleculin Announces Notice of Allowance for Japanese Patent Covering Annamycin

MBRX

Moleculin Biotech announces launch of CEO Corner platform

2026-02-13T13:35:29.000Z - 6 months ago

Moleculin Biotech announces launch of CEO Corner platform

MBRX

Moleculin Launches CEO Corner Platform to Share Strategic Insights

Feb 13, 2026, 8:32 AM EST - 6 months ago

Moleculin Launches CEO Corner Platform to Share Strategic Insights

MBRX

Moleculin Biotech Transcript: Corporate Connect Webinar Series

Feb 11, 2026, 1:20 PM EST - 6 months ago

Moleculin Biotech Transcript: Corporate Connect Webinar Series

Moleculin to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial

Feb 5, 2026, 9:15 AM EST - 6 months ago

Moleculin to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial

MBRX

Moleculin Biotech reports assessment confirms no cardiotoxicity of Annamycin

2026-01-13T14:01:57.000Z - 7 months ago

Moleculin Biotech reports assessment confirms no cardiotoxicity of Annamycin

MBRX

Moleculin Reports Independent Assessment Confirms No Cardiotoxicity of Annamycin in 90 Subjects

Jan 13, 2026, 8:55 AM EST - 7 months ago

Moleculin Reports Independent Assessment Confirms No Cardiotoxicity of Annamycin in 90 Subjects

MBRX

Moleculin Biotech says first MIRACLE trial unblinding expected in 1Q16

2026-01-12T13:46:34.000Z - 7 months ago

Moleculin Biotech says first MIRACLE trial unblinding expected in 1Q16

MBRX

Moleculin Accelerates Outlook Into 2026 With First Pivotal Trial Unblinding on Track, Global Trial Expansion, and Multiple Externally/IIT Funded Clinical Programs

Jan 12, 2026, 8:36 AM EST - 7 months ago

Moleculin Accelerates Outlook Into 2026 With First Pivotal Trial Unblinding on Track, Global Trial Expansion, and Multiple Externally/IIT Funded Clinical Programs

MBRX

Moleculin Biotech Proxy statement: Proxy Filing

Jan 2, 2026, 7:00 AM EST - 8 months ago

Moleculin Biotech Proxy statement: Proxy Filing

Moleculin Biotech files to sell 2.61M shares of common stock for holders

2025-12-23T21:50:21.000Z - 8 months ago

Moleculin Biotech files to sell 2.61M shares of common stock for holders

MBRX

Moleculin Biotech Registration statement: Registration Filing

Dec 23, 2025, 7:00 AM EST - 8 months ago

Moleculin Biotech Registration statement: Registration Filing

Moleculin Biotech Proxy statement: Proxy Filing

Dec 22, 2025, 7:00 AM EST - 8 months ago

Moleculin Biotech Proxy statement: Proxy Filing

Moleculin Biotech Proxy statement: Proxy Filing

Dec 19, 2025, 7:00 AM EST - 8 months ago

Moleculin Biotech Proxy statement: Proxy Filing

Moleculin Biotech announces results from Phase 1 trial of WP1066

2025-12-17T13:36:21.000Z - 8 months ago

Moleculin Biotech announces results from Phase 1 trial of WP1066

MBRX

Moleculin Announces Positive Results from Phase 1 Clinical Trial Evaluating WP1066 for the Treatment of Pediatric Recurrent Malignant Brain Tumors

Dec 17, 2025, 8:31 AM EST - 8 months ago

Moleculin Announces Positive Results from Phase 1 Clinical Trial Evaluating WP1066 for the Treatment of Pediatric Recurrent Malignant Brain Tumors

MBRX

Moleculin Biotech target adjusted to $31 from $300 at Roth Capital

2025-12-15T17:20:30.000Z - 8 months ago

Moleculin Biotech target adjusted to $31 from $300 at Roth Capital

MBRX

Moleculin Announces Exercise of Warrants for $6.8 Million Gross Proceeds

Dec 10, 2025, 8:30 AM EST - 9 months ago

Moleculin Announces Exercise of Warrants for $6.8 Million Gross Proceeds

MBRX

Moleculin Announces Completion of Treatment for the 45 Patients in Pivotal “MIRACLE” Phase 3 AML Trial on Pace for Q1 2026

Dec 9, 2025, 8:07 AM EST - 9 months ago

Moleculin Announces Completion of Treatment for the 45 Patients in Pivotal “MIRACLE” Phase 3 AML Trial on Pace for Q1 2026

MBRX

Moleculin Announces New Annamycin Collaboration in Brain Tumors

Dec 8, 2025, 8:21 AM EST - 9 months ago

Moleculin Announces New Annamycin Collaboration in Brain Tumors

MBRX

Moleculin to Participate in the Virtual Investor Closing Bell Series

Nov 26, 2025, 9:15 AM EST - 9 months ago

Moleculin to Participate in the Virtual Investor Closing Bell Series

MBRX

Moleculin Announces Reverse Stock Split

Nov 26, 2025, 9:00 AM EST - 9 months ago

Moleculin Announces Reverse Stock Split

MBRX

Moleculin Reports 60% of First 45 Subjects in Pivotal “MIRACLE” Phase 3 AML Trial Consented

Nov 13, 2025, 8:36 AM EST - 9 months ago

Moleculin Reports 60% of First 45 Subjects in Pivotal “MIRACLE” Phase 3 AML Trial Consented

MBRX

Moleculin Biotech Quarterly report: Q3 2025

Nov 13, 2025, 7:00 AM EST - 9 months ago

Moleculin Biotech Quarterly report: Q3 2025

Moleculin Announces Grant Funded Research Evaluating Annamycin for the Treatment of Pancreatic Cancer at UNC-Chapel Hill

Nov 12, 2025, 8:37 AM EST - 10 months ago

Moleculin Announces Grant Funded Research Evaluating Annamycin for the Treatment of Pancreatic Cancer at UNC-Chapel Hill

MBRX

Moleculin to Highlight its Ongoing Phase 3 Acute Myeloid Leukemia “MIRACLE” Clinical Trial at the 14th Annual Acute Leukemia Meeting

Oct 30, 2025, 8:40 AM EDT - 10 months ago

Moleculin to Highlight its Ongoing Phase 3 Acute Myeloid Leukemia “MIRACLE” Clinical Trial at the 14th Annual Acute Leukemia Meeting

MBRX

Moleculin Expands Global IP Portfolio with New Australian Patent for Annamycin

Oct 29, 2025, 8:35 AM EDT - 10 months ago

Moleculin Expands Global IP Portfolio with New Australian Patent for Annamycin

MBRX

Moleculin Announces New Investigator-Initiated Study of Annamycin for Treating Pancreatic Cancer

Oct 23, 2025, 8:00 AM EDT - 10 months ago

Moleculin Announces New Investigator-Initiated Study of Annamycin for Treating Pancreatic Cancer

MBRX

Moleculin Announces Notice of Allowance for Canadian Patent Covering Annamycin

Sep 25, 2025, 8:35 AM EDT - 11 months ago

Moleculin Announces Notice of Allowance for Canadian Patent Covering Annamycin

MBRX

Moleculin Biotech Registration statement: Registration Filing

Sep 19, 2025, 8:00 AM EDT - 11 months ago

Moleculin Biotech Registration statement: Registration Filing

Moleculin Biotech Proxy statement: Proxy Filing

Sep 15, 2025, 8:00 AM EDT - 1 year ago

Moleculin Biotech Proxy statement: Proxy Filing

Moleculin Accelerates Recruitment in Phase 3 Acute Myeloid Leukemia “MIRACLE” Clinical Trial

Sep 9, 2025, 8:45 AM EDT - 1 year ago

Moleculin Accelerates Recruitment in Phase 3 Acute Myeloid Leukemia “MIRACLE” Clinical Trial

MBRX

Moleculin Doses First EU Patient in Phase 3 Pivotal MIRACLE Trial for Treatment of Acute Myeloid Leukemia

Sep 8, 2025, 8:30 AM EDT - 1 year ago

Moleculin Doses First EU Patient in Phase 3 Pivotal MIRACLE Trial for Treatment of Acute Myeloid Leukemia

MBRX

Moleculin Biotech Proxy statement: Proxy Filing

Sep 5, 2025, 8:00 AM EDT - 1 year ago

Moleculin Biotech Proxy statement: Proxy Filing

Moleculin Announces Exercise of Warrants for $6.0 Million Gross Proceeds

Aug 28, 2025, 8:30 AM EDT - 1 year ago

Moleculin Announces Exercise of Warrants for $6.0 Million Gross Proceeds

MBRX

Moleculin Issues New Positive AML Overall Survival Data:

Aug 27, 2025, 8:45 AM EDT - 1 year ago

Moleculin Issues New Positive AML Overall Survival Data:

MBRX

Moleculin to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

Aug 14, 2025, 9:15 AM EDT - 1 year ago

Moleculin to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

MBRX

Moleculin Reports Second Quarter 2025 Financial Results and Highlights

Aug 13, 2025, 8:05 AM EDT - 1 year ago

Moleculin Reports Second Quarter 2025 Financial Results and Highlights

MBRX

Moleculin Biotech Earnings release: Q2 2025

Aug 13, 2025, 8:00 AM EDT - 1 year ago

Moleculin Biotech Earnings release: Q2 2025

Moleculin Biotech Quarterly report: Q2 2025

Aug 13, 2025, 8:00 AM EDT - 1 year ago

Moleculin Biotech Quarterly report: Q2 2025

Moleculin Biotech, Inc. Unveils Promising Preclinical Data of Annamycin in Liver Cancer Treatment

Aug 6, 2025, 8:40 AM EDT - 1 year ago

Moleculin Biotech, Inc. Unveils Promising Preclinical Data of Annamycin in Liver Cancer Treatment

MBRX

Moleculin Receives Notice of Intent to Grant New European Patent for Annamycin

Jul 30, 2025, 8:35 AM EDT - 1 year ago

Moleculin Receives Notice of Intent to Grant New European Patent for Annamycin

MBRX

Moleculin Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand Conference

Jul 22, 2025, 8:45 AM EDT - 1 year ago

Moleculin Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand Conference

MBRX

Moleculin Engages Industry Veteran Adriano Treve to Explore Accelerated Strategic Partnerships

Jul 17, 2025, 8:25 AM EDT - 1 year ago

Moleculin Engages Industry Veteran Adriano Treve to Explore Accelerated Strategic Partnerships

MBRX

Moleculin Expands Phase 3 MIRACLE Clinical Trial into the Country of Georgia, Enrollment Update and Future Plans

Jul 9, 2025, 8:35 AM EDT - 1 year ago

Moleculin Expands Phase 3 MIRACLE Clinical Trial into the Country of Georgia, Enrollment Update and Future Plans

MBRX

Traveladvisor
Traveladvisor Aug. 19 at 3:33 PM
$MBRX
0 · Reply
Traveladvisor
Traveladvisor Aug. 19 at 3:32 PM
$MBRX A big catalyst is coming, partnership? The short squeeze is ready, get in while you can.
0 · Reply
Traveladvisor
Traveladvisor Aug. 18 at 1:38 PM
$MBRX
1 · Reply
ShangVXO
ShangVXO Aug. 18 at 12:07 PM
Been tapped into @_ProfessorGamma for a minute now. The way they spot some of these plays before they run is nuts! Wise to be paying attention to this account, give him a proper follow 👍 $MBRX and $NIVF on my radar
2 · Reply
Big_Zack22
Big_Zack22 Aug. 17 at 8:01 PM
$MBRX Hold on a good consolidation. Next hope 0.85 then we fly
0 · Reply
Stormra
Stormra Aug. 17 at 7:53 PM
$MBRX Not one post all day accept mine.????
0 · Reply
Stormra
Stormra Aug. 17 at 2:27 PM
$MBRX Hello.... Lets go!!!
0 · Reply
Big_Zack22
Big_Zack22 Aug. 17 at 1:19 AM
$MBRX The recent sell-off created an asymmetrical upside setup. MBRX has a funded cash runway into Q1 2027 following its $9.3M offering, removing immediate dilution risk. Unblinded interim data for its Phase 2/3 MIRACLE trial showed 50-57% complete remission rates (vs 29% control) with zero cardiotoxicity, solving anthracycline heart-damage risks. Part A enrollment finishes by Sept 2026, with major unblinded results due Dec-Feb. At current oversold levels, clinical catalysts can easily trigger a powerful rally.
0 · Reply
Big_Zack22
Big_Zack22 Aug. 17 at 12:17 AM
$MBRX will aggressively recover, all points to an upward.
0 · Reply
Komba123
Komba123 Aug. 16 at 8:55 PM
$FAMI $MBRX $SPY im Bullish but it’s not 50% short float, it’s about 7%
0 · Reply
Paraboljoker
Paraboljoker Aug. 16 at 8:53 PM
$FAMI loading size tomorrow 50% Of float short .Compliance resolved with Nasdaq window open feb 2027 and Brazil commodity deal still in framework stage. $1 cash per shares trades for a 90% discount, Nobrainer 🐂🐂🐂🐂🐂 $SPY #OPTIONS $MBRX adding to watchlist
1 · Reply
KoalaFlipper
KoalaFlipper Aug. 16 at 7:08 PM
$MBRX 🚀🐂
0 · Reply
LIT_L7
LIT_L7 Aug. 15 at 3:08 PM
$MBRX If Wally gets the share price over a dollar for a day in the 30 day time period we're good. If not, with the new rules... to the pink sheets. Hey, I don't like that fact but it is a possibility. We have to remember the MVLS of 5 million. The sec has suspended this requirement as it reviews the policy. Nasdaq wants it and is enforceable after 30 days. OK, leaving on a good note, if MBRX does go to the otc market, there is no pressing issue to do a r/s. Yeah. Transparency from Wally and Co. would stop most of the speculation. Lets toast the weekend. Cheers-
0 · Reply
chanvekse
chanvekse Aug. 14 at 10:32 PM
$MBRX 👀 Something VERY interesting in today’s PRE 14A that deserves attention. Certain management performance awards are tied to major milestones, including the first occurrence of: 🔥 A licensing transaction valued at MORE THAN $150M 🔥 An NDA filing 🔥 A CHANGE IN CONTROL Management’s incentive structure explicitly contemplates a major licensing transaction or potential acquisition/change of control. Does this mean a $150M+ deal or buyout is coming? NO. There is no announced transaction. But with MIRACLE approaching 90-patient Part A results and MBRX needing future funding, seeing $150M+ licensing and Change in Control specifically built into management incentives is definitely interesting. 👀🔥 Something to keep on the radar. $MBRX
1 · Reply
chanvekse
chanvekse Aug. 14 at 10:30 PM
$MBRX 🔥Another Interesting setup in today’s PRE 14A. Shareholders will vote Oct 9 to authorize a 1:2–1:20 reverse split — BUT authorization does NOT mean it automatically happens. The Board gets discretion on whether/when to use it. To me, this looks like Nasdaq insurance while MBRX heads into major catalysts: 🔥 Part A enrollment completion expected Sept 🔥 90-patient unblinded data Dec–Feb 🔥 Potential partnership/licensing opportunities If catalysts can get $MBRX back above $1 organically, would they even need to use the reverse split? Nothing guaranteed, but the next few months could get VERY interesting. 👀🚀 IMO. Do your own DD.
0 · Reply
Pepe_The_Short
Pepe_The_Short Aug. 14 at 9:14 PM
$MBRX Ive Owned MBRX since 2022. Down 99k so far. Time for reversal soon
0 · Reply
BRDUPO
BRDUPO Aug. 14 at 4:51 PM
$MBRX was reverse split down to 1 share with a recovery price of $2300. let's see...
0 · Reply
DANIELE2
DANIELE2 Aug. 14 at 3:57 PM
$MBRX target by end of the day?
1 · Reply
KoalaFlipper
KoalaFlipper Aug. 14 at 3:44 PM
$MBRX If Moleculin Biotech Inc. (NASDAQ: MBRX) continues to release good news, it could trigger a highly volatile upward stock reaction, accelerate FDA fast-track pathways, and attract major pharmaceutical buyouts or partnerships. However, because Moleculin is a micro-cap company with a historically depressed share price, any positive news would immediately collide with its urgent need for capital, potentially triggering share dilution.
0 · Reply
KoalaFlipper
KoalaFlipper Aug. 14 at 3:42 PM
$MBRX Short Interest Float 36.49 % Inst Own 22.13%
0 · Reply
KoalaFlipper
KoalaFlipper Aug. 14 at 2:04 PM
$OTLK maybe take a look at $MBRX just a tip.
0 · Reply
KoalaFlipper
KoalaFlipper Aug. 14 at 1:59 PM
$MBRX 🚀📈🙏🐂🐂🐂
0 · Reply